ClinicalTrials.gg
Enrolling by invitationNCT06138548Updated Aug 17, 2026

Bio-Integrative, Fiber-Reinforced Kneebar for Treating Subchondral Insufficiency of the Knee

An observational study in Subchondral Insufficiency Fracture, sponsored by Stanford University. Enrolling by invitation at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Stanford University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10
Ages
18 Years and older
Sex
All
01

Study summary

The OSSIOfiber® Trimmable Fixation Nails are indicated for maintenance of alignment and fixation of bone fractures, osteotomies, arthrodesis and bone grafts in the presence of appropriate additional immobilization (e.g., rigid fixation implants, cast, brace). The hypothesis is that the use of OSSIOfiber® Trimmable Fixation Nails for treating subchondral insufficiency of the knee will result in improvement of patient-reported outcomes and imaging findings. The primary objective of this study is to evaluate the effectiveness of implanting bio-integrative OSSIOfiber® Trimmable Fixation Nails, organized in a bi-cortical rafter formation within the tibia or femur for the management of subchondral insufficiency. This use is not considered off-label because the TFNs are being used in the way they are intended to be used via FDA approval.

02

Conditions studied

  • Subchondral Insufficiency Fracture

Browse trials for

Keywords

  • Ossio
  • Kneebar
  • Fracture
  • Subchondral insufficiency
  • Tibial overload
  • Femoral Overload
03

In context

Fractures, Bone

723 studies on the registry are indexed under Fractures, Bone; 114 are open to participants now.

This study's planned enrollment of 10 is below the median of 130 across 239 observational studies indexed under Fractures, Bone.

Browse Fractures, Bone studies →

Lead sponsor

Stanford University is the lead sponsor of 2,168 studies on the registry; 431 are open to participants now.

Of its 267 completed or terminated interventional studies of FDA-regulated products, 207 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Those who have subchondral insufficiency of the knee with tibial or femoral overload.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has had knee pain in study knee lasting at least 3 months
  2. Candidate for knee arthroscopy due to meniscal tear, loose body, unstable articular cartilage or mechanical symptoms.

Exclusion criteria

Exclusion Criteria:

  1. Current tobacco use or has quit within 3 months of study enrolment.
  2. Substance abuse history.
  3. Diabetes mellitus, >8
  4. High surgical risk due to pre-existing conditions.
  5. Currently pregnant or has plans to become pregnant prior to surgery.
  6. Active infection or history of chronic infection in study knee.
  7. Will require concomitant procedures within study knee, including but not limited to ligament reconstruction, tendon repair, meniscus repair, microfracture, osteotomy, or osteochondral transplantation. (Meniscal tears, including chronic, are acceptable if no repair is required)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10 participants (estimated)
Patient registry
No

Groups and cohorts

  • Subchondral Insufficiency

    Those who have subchondral insufficiency with tibial or femoral overload in the knee and are receiving the TFNs as standard of care.

    Device: Ossiofiber® Trimmable Fixation Nail

Interventions

  • DeviceOssiofiber® Trimmable Fixation Nail

    OSSIOfiber® Trimmable Fixation Nails are equally strong in the initial stability and fixation strength - and superior in rotational resistance to traditional metal cannulated headless compression screws.\*

06

What researchers measure

Primary outcomes

  1. Knee injury and Osteoarthritis Outcome Score (KOOS)

    The overall KOOS score combines pain and function domains. KOOS is out 100, where 0 equates to extreme pain and 100 equates to no pain.

    Time frame: 3 months post-operatively

  2. Knee injury and Osteoarthritis Outcome Scale Score (KOOS)

    The overall KOOS score combines pain and function domains. KOOS is out 100, where 0 equates to extreme pain and 100 equates to no pain.

    Time frame: 6 months post-operatively

Secondary outcomes

  1. Knee injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS, JR.)

    Measures the knee health of individuals following surgery

    Time frame: 6 months post-operatively

  2. International Knee Documentation Committee (IKDC) Subjective Knee Evaluation Form

    IKDC measures: symptoms, athletic activity, and knee function.

    Time frame: 6 months post-operatively

  3. Veterans Rand-12 (VR-12) Health Survey Scale Score

    VR-12 combines measures of general health perceptions, physical functioning, role limitations due to physical and emotional problems, bodily pain, fatigue , social functioning, and mental health

    Time frame: 6 months post-operatively

  4. Numeric Pain Reported Scale Score

    Measures a subject's perceived pain level. This score is usually on a scale of 0-10 with 0 equating to no pain and 10 equating to the worst pain imaginable.

    Time frame: 6 months post-operatively

  5. PROMIS Pain Interference Score

    Measures what level pain hinders a patient's engagement in several activities including social, cognitive, physical, and recreational activities. There are 7 sub items and each are rated from a scale of 0-10 where 0 means it does not interfere and 10 means it completely interferes. These contribute to a final score ranging anywhere from 0-70.

    Time frame: 6 months post-operatively

  6. PROMIS Depression Score

    Measures self-reported negative mood (sadness, guilt), views of self (self- criticism, worthlessness), and social cognition (loneliness, interpersonal alienation), as well as decreased positive affect and engagement (loss of interest, meaning, and purpose). Each item on the measure is rated on a 5-point scale (1=never; 2=rarely; 3=sometimes; 4=often; and 5=always) with a range in score from 8 to 40. Higher scores indicate greater severity of depression.

    Time frame: 6 months post-operatively

  7. PROMIS Physical Function Score

    Measures the level of physical function for patients with a wide variety of impairments that may limit the patient's physical capability. This score is on a scale from 0-100 with 0 equating to no physical function and 100 equating to optimal physical function.

    Time frame: 6 months post-operatively

  8. Incidence Assessments

    Assessment of the incidence of re-operations, revision surgeries, or additional management of the study knee outside of postoperative rehabilitation.

    Time frame: Up to 24 month post-operatively.

  9. Degree of knee ligament healing

    To see how the knee ligament is healing by MRI assessment.

    Time frame: 6, 12, and 24 months

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06138548
Responsible party
Seth Sherman (Associate Professor, Stanford University) — Principal investigator
First posted
Nov 18, 2023
Start date
Oct 31, 2025
Primary completion
Jul 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Aug 17, 2026

Study contacts

Seth L Sherman, MD
principal investigator · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion